Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

ng more than offset by the previous fiscal year's cost associated with the Company's annual shareholder meeting.

Loss for the period

The Company recorded a loss of $1,526,000 and $3,170,000, respectively, for the three and six month periods ended January 31, 2008, for a loss per common share of $0.04 and $0.08, respectively. In the comparative three and six month periods ended January 31, 2007, the Company recorded a loss $1,900,000 and $3,242,000, respectively, for a loss per common share of $0.05 and $0.09, respectively.

Revenues

Total revenues for the three month period ended January 31, 2008 was $791,000, compared to revenues of $892,000 for the same period last year. This represents a decrease of $101,000, or 11.3%. Total revenues for the six month period ended January 31, 2008, was $1,676,000, compared to $1,718,000 a year ago. This represents a decrease of $42,000, or 2.4%.

Product Revenue

Product revenue totaled $652,000 and $1,406,000, respectively, for the three and six month periods ended January 31, 2008 and represent a decrease of $105,000 (13.9%) and $47,000 (3.2%), respectively, when compared to same periods last year. Higher revenues from the sale of Klean-Prep(TM) in Canada were not sufficient to offset lower revenues from the sale of Orthovisc(R) in the three and six month periods ended January 31, 2008.

License Fees and Royalty Revenue

License fees and royalties totaled $139,000 and $270,000, respectively, for the three and six month periods ended January 31, 2008, and represent a slight increase of $4,000 (3.0%) and $5,000 (1.9%), respectively, when compared to same periods a year ago. The license fees and royalties for both the three and six month periods ended January 31, 2008, and 2007 are comprised solely of royalties related to sales of Klean-Prep(TM) outside of Canada.

Cost of sales and margins

Cost of sales totaled $269,000 and $582,000, respectively, for the three and s
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... cell fragments whose job it is to stop bleeding, ... But they can "feel" the physical environment around them, ... Platelets respond to surfaces with greater stiffness by increasing ... other platelets and other components of the clotting system, ... give them credit for, in that they are able ...
(Date:9/22/2014)... a highly sensitive chemical sensor based on the crystalline ... properties that the researchers were able to exploit to ... , The study is available online in advance of ... Khojin, asst professor of mechanical and industrial engineering in ... Kumar, post doc where they are doing research in ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 Topical ... helping those in pain end their suffering, restoring hope ... healthcare model. This is only possible because of the ... and healing cream technology a reality. , The ... Rhinebeck, NY, by Lou Paradise (president, chief of research, ...
(Date:9/22/2014)... 22, 2014 Invisible Sentinel Inc., ... the food and beverage industries, announced today that ... under a non-exclusive agreement by Enartis, a global ... Enartis, an Esseco Group company headquartered in Trecate, ... California and other global markets for their own ...
Breaking Biology Technology:Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3
... ... and Genedata Expressionist® at Evonik for Industrial Biotechnology R&D Processes , ... Basel, Switzerland (PRWEB) ... industrial biotechnology R&D, today announced an extended partnership with Evonik, a leading life ...
... ... ... , ... , , , ...
... in the development of practical phonon lasers, which emit sound ... The development should lead to new, high-resolution imaging devices and ... countless, ubiquitous devices, a phonon laser is likely to be ... Two separate research groups, one located in the US and ...
Cached Biology Technology:Evonik Extends Long-term Research & Development Partnership with Genedata 2Evonik Extends Long-term Research & Development Partnership with Genedata 3Evonik Extends Long-term Research & Development Partnership with Genedata 4Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine 2Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine 3Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine 4Quantum leap for phonon lasers 2
(Date:9/21/2014)... what was previously thought, newborn immune T cells may ... bacteria, according to a new study led by King,s ... to that of adults, babies may still be able ... published in the journal Nature Medicine . , ... types of immune cells, including neutrophils which play an ...
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
(Date:9/19/2014)... are a species which over thousands of years has adapted ... a substance that makes the cold dangerous for you. , ... albidus , and the cold provoking substance, called nonylphenol, comes ... Nonylphenol is suspected of being a endocrine disruptor, but when ... the worm,s ability to protect the cells in its body ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... average life expectancy and decreases recurrences of tumors in ... according to researchers at Rhode Island Hospital. , In ... the median survival rate at three years increased from ... thermal ablation was followed by radiation for treatment of ...
... a study comparing wild rodents with their laboratory counterparts, ... that may help to explain why people in industrialized ... allergy and autoimmune diseases than do people in less ... or considered less critical. , The prevailing hypothesis concerning ...
... week's Analytical Chemistry, scientists at Indiana University Bloomington ... to follow the weakest of scents. Even when ... cells still found their mark. , A video ... a chemical gradient) can be downloaded at ...
Cached Biology News:Combined treatment extends life expectancy for lung cancer patients 2Combined treatment extends life expectancy for lung cancer patients 3Wild vs. lab rodent comparison supports hygiene hypothesis 2Wild vs. lab rodent comparison supports hygiene hypothesis 3Wild vs. lab rodent comparison supports hygiene hypothesis 4Even when faint, ovary scent draws sperm cells 2
Proliferin (C-14)...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... Ascent is a dedicated fluorometer ... all kinds of assays in ... for clinical applications. Cell biology, ... all important application areas. Robot-friendly ...
... Thermo Savant's latest SpeedVac Concentrator, the ... and adds a new modern twist., The ... controller and gauge for optimizing runs; preventing ... to be stopped at the end-users preset ...
Biology Products: